An Overview of Pritor®/Kinzal®:
the only cardiometabolic ARB
Dual activity
Telmisartan (Pritor®/Kinzal®) is an Angiotension Receptor Blocker (ARB) with dual activity, acting through AT1 receptor blockade and selective PPAR-γ (peroxisome proliferator-activated receptor-gamma) modulation to provide strong blood pressure control with potential additional metabolic benefits.2
more
Strong blood pressure control
Reduction in systolic blood pressure is one of the key factors in minimising cardiovascular risk. Pritor®/Kinzal® has demonstrated a stronger reduction in both systolic and diastolic blood pressure compared to other ARBs.3
more
Efficacy maintained over 24 hours with a single dose
Pritor®/Kinzal® provides control of hypertension over a 24-hour period including the critical 6 morning hours during which hypertensive patients are at increased risk of stroke and myocardial infarction.4
more
Cardiovascular and renal protection
The recently published ONTARGET® and PROTECTION® study programmes have demonstrated Pritor®/Kinzal®'s cardiovascular and renal protection.
The ONTARGET® trial has shown that Pritor®/Kinzal® is as effective as ramipril in reducing the risk of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure (combined endpoint) in high cardiovascular risk patients, but with better tolerability. There were more discontinuations in the ramipril group than in the Pritor®/Kinzal® group due to angio-oedema and cough, although more patients in the Pritor®/Kinzal® group discontinued because of hypotensive symptoms.5
In addition, the PROTECTION® study programme has demonstrated Pritor®/Kinzal®’s renoprotective effect across the renal continuum.6
For more information on these trials along with the data and opinions from leading experts on the potential implications for clinical practice, please visit www.ICMAedu.com.
High tolerability, even in ACE Inhibitor tolerant patients
In the ONTARGET® trial, despite greater discontinuation due to hypotensive symptoms, overall Pritor®/Kinzal® was associated with greater tolerability and higher treatment compliance than the comparator ACE inhibitor ramipril, even amongst an entirely ACE inhibitor tolerant population.5
more
Additional metabolic benefits
Through its dual mode of action, Pritor®/Kinzal® influences blood pressure and has potential to improve other cardiometabolic risk factors. AT1 receptor inhibition results in significant blood pressure reduction whilst selective PPAR-γ modulation (SPPARM) may improve associated metabolic parameters including lipid and glucose levels.7
For more information on the benefits of Pritor®/Kinzal® please consult the following detailed pages:
more
